Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | OGA | O60502 | 7/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MANBA | O00462 | 1/20 | 0.40 |
| ▸ | PYGB | P11216 | 5/20 | 0.38 |
| ▸ | SLC28A3 | Q9HAS3 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9297697 | 1.00 | GBA1 (0.55) | GBA1LMNAOGATSHRGAA | |
| SCHEMBL4207953 | 1.00 | GBA1 (0.55) | GBA1LMNAOGATSHRGAA | |
| SCHEMBL8495531 | 0.94 | GBA1 (0.47) | GBA1LMNAOGATSHRGAA | |
| SCHEMBL5666062 | 0.94 | GBA1 (0.47) | GBA1LMNAOGATSHRGAA | |
| SCHEMBL18427840 | 0.81 | OGA (0.45) | GBA1LMNAOGATSHRGAA | |
| SCHEMBL3675624 | 0.81 | GBA1 (0.55) | GBA1LMNAOGATSHRGAA | |
| SCHEMBL17978030 | 0.77 | GBA1 (0.50) | GBA1LMNAOGATSHRGAA | |
| SCHEMBL668693 | 0.77 | GBA1 (0.50) | GBA1LMNAOGATSHRGAA | |
| SCHEMBL5162383 | 0.74 | SMN1; SMN2 (0.37) | — | |
| Gluconolactone SCHEMBL24637666 | 0.71 | LMNA (1.00) | GBA1LMNAOGAGAAMANBA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6122625-A | — | — | None | — | — | JP | disclosed |
| EP-4255916-A2 | TERPENOID DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN NEUROPROTECTION | Univerzita Palackého v Olomouci (CZ) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022117133-A2 | TERPENOID DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN NEUROPROTECTION | Univerzita Palackého v Olomouci (CZ) | 2022-06-09 | — | — | WO | disclosed |
| US-9549986-B2 | Block copolymer, liquid composite thereof, nucleic acid preparation, preparation methods therefor, and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2017-01-24 | — | — | US | disclosed |
| EP-3079785-A1 | ARRAY OF AGE-TAILORED NUTRITIONAL FORMULAE WITH OPTIMUM MINERAL NUTRIENT CONTENT | Nestec S.A. (CH) | 2016-10-19 | — | — | EP | disclosed |
| EP-3079505-A1 | ARRAY OF AGE-TAILORED INFANT FORMULA WITH OPTIMUM PROTEIN CONTENT AND LACTOSE CONTENT | Nestec S.A. (CH) | 2016-10-19 | — | — | EP | disclosed |
| EP-3079844-A1 | ARRAY OF AGE-TAILORED INFANT FORMULA WITH OPTIMUM PROTEIN CONTENT AND LACTOSE CONTENT | Nestec S.A. (CH) | 2016-10-19 | — | — | EP | disclosed |
| EP-2900256-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) INJURY | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2015-08-05 | — | — | EP | disclosed |
| WO-2015085551-A1 | ARRAY OF AGE-TAILORED NUTRITIONAL FORMULAE WITH OPTIMUM MINERAL NUTRIENT CONTENT | NESTEC S.A. (CH) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086173-A1 | ARRAY OF AGE-TAILORED INFANT FORMULA WITH OPTIMUM PROTEIN CONTENT AND LACTOSE CONTENT | NESTEC S.A. (CH) | 2015-06-18 | — | — | WO | disclosed |
| EP-1993576-A1 | SYNBIOTIC MIXTURE | NESTEC S.A. (CH) | 2008-11-26 | — | — | EP | disclosed |
| EP-1988786-A1 | OLIGOSACCHARIDE MIXTURE | NESTEC S.A. (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007125429-A2 | METHOD FOR THE SYNTHESIS OF TRIAZOLE- CONTAINING OLIGONUCLEOTIDE DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007101675-A1 | SYNBIOTIC MIXTURE | NESTEC S.A. (CH) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007090894-A1 | OLIGOSACCHARIDE MIXTURE | NESTEC S.A. (CH) | 2007-08-16 | — | — | WO | disclosed |
| US-20050203061-A1 | Prodrug, medicinal utilization thereof and process for producing the same | NIPPON SUISAN KAISHA, LTD. (JP) | 2005-09-15 | — | — | US | disclosed |
| EP-1541579-A1 | PRODURG, MEDICINAL UTILIZATION THEREOF AND PROCESS FOR PRODUCING THE SAME | Nippon Suisan Kaisha, Ltd. (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2001038545-A1 | A NOVEL POLYPEPTIDE, A HUMAN ACETYL GALACTOSYL TRANSFERASE 45 AND THE POLYNUCLEOTIDE ENCODING THE POLYPEPTIDE | BIOROAD GENE DEVELOPMENT LTD. SHANGHAI (CN) | 2001-05-31 | — | — | WO | disclosed |
| WO-1997014707-A1 | SIALYL Lex ANALOGUES AS INHIBITORS OF CELLULAR ADHESION | CYTEL CORPORATION (US) | 1997-04-24 | — | — | WO | disclosed |
| JP-H06122625-A | ENDOTHELIN RECEPTOR ANTAGONISTIC AGENT | ASAHI CHEM IND CO LTD | 1994-05-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203061-A1 | Prodrug, medicinal utilization thereof and process for producing the same | ENGASE, GALE, GUSB | GBA1 64/4885LMNA 2379/4885OGA 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.